The solution to sustainability is not as simple as passing costs onto the customer… Oregon’s service centers are where people go to have a therapeutic psilocybin experiece or a guided trip, if you will. (In Colorado, these facilities are called “healing centers.”) But in Oregon, owners say the cost of doing business is so expensive…
The U.S. Department of Justice announced that the chief executive officer of psilocybin company Minerco Inc. (OTC: MINE), Julius Jenge was arrested… The former CEO was fleeing a Securities and Exchange Commission (SEC) investigation into the stock fraud allegations around the penny stock company Minerco… In 2021, the company began touting its psilocybin business and Minerco…
“I’m not going to go smoke pot and hang out on my couch for the next 20 years,” he said in an interview, criticizing the agency for failing to grasp the drug’s potential to relieve suffering. Still, it has been a brutally rough stretch for Doblin and MAPS, which over decades have shepherded an illegal…
It claims to be the first publicly owned service center in the U.S., with penny-priced stock that investors can buy if they’d like to cash in on the shroom boom… cannabis was a ripe market for stock schemes back then, says Vince Sliwoski, a Portland lawyer who advises cannabis and psilocybin firms. It was the…
Narrowly tailoring deflection offerings to just possession charges – not the low-level public disorder crimes that often accompany drug use – means counties “are going to miss 98% of what’s really bugging everyone,’ said Lisa Daugaard, a Seattle attorney and key architect of the LEAD model… “LEAD is intended to be a public safety, public…
The donation shows that Dr. Bronner’s is doubling down on the Oregon experiment with psilocybin despite its troubles, as outlined in Willamette Week’s cover story… service centers are struggling to make it, costs are high, and surprising backers are showing up. Bendable Therapy… the nonprofit pairs clients with licensed guides at partner facilities for psilocybin treatment.…
Lykos and its founder, Rick Doblin, have for years tried to persuade regulators and the pharmaceutical industry at large that psychedelic drugs should be used in the treatment of certain mental health conditions. “After 38 plus years of work, I’m profoundly saddened by the FDA decision around this critically needed therapy, but am heartened that…
[Friday, August 9, 2024] “…it is time for Commissioner [Robert] Califf to exercise direct oversight and order the Agency [FDA] to reassess its biased attacks on kratom and psychedelics,” Mac Haddow, senior fellow of public policy for American Kratom Association… August 12, 2024; The Food and Drug Administration (FDA) has withdrawn a request for White…
The FDA declined to approve the new treatment submitted by Lykos Therapeutics, an organization that develops innovations to “transform mental healthcare,” deciding that there still isn’t enough evidence of benefit to outweigh the risks. The decision will have far-reaching ripple effects. Some psychedelic advocates will have to put celebrations they’ve been planning for decades on pause;…
A 77-year-old retired Marine Corps general has emerged as an unlikely advocate for treating veterans suffering from post-traumatic stress disorder with the psychedelic drug ecstasy… Jack Bergman flew helicopters in Vietnam, earned three stars, and is now in his fourth term representing a northern Michigan district in the House. A Republican, he sees promise in…
Recent Comments